Simultaneous quantification of infliximab and adalimumab in human plasma by liquid chromatography-tandem mass spectrometry using ready-to-use kit and comparison with two ELISA methods

被引：0

作者：

Tron, C. ^{[1
]}

Lemaitre, F. ^{[1
]}

Bros, P. ^{[2
]}

Goulvestre, C. ^{[3
]}

Franck, B. ^{[1
]}

Mouton, N. ^{[2
]}

Bagnos, S. ^{[2
]}

Coriat, R. ^{[4
]}

Bellissant, E. ^{[1
]}

Khoudour, N. ^{[5
]}

Lebert, D. ^{[2
]}

Blanchet, B. ^{[5
]}

机构：

[1] Univ Rennes, CHU Rennes, IRSET Inst Rech Sante Environm & Travail, INSERM,EHESP,Pharmacol Dept,UMR S 1085, Rennes, France

[2] Promise Prote, Grenoble, France

[3] Cochin Hosp, AP HP Ctr, Dept Immunol, Paris, France

[4] Univ Paris, Cochin Hosp, AP HP Ctr, Dept Gastroenterol, Paris, France

[5] Cochin Hosp, AP HP Ctr, Dept Pharmacokinet & Pharmacochem, Paris, France

来源：

关键词：

therapeutic drug monitoring; infliximab; adalimumab; LC-MS/MS; ELISA;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

PS-035

引用

页码：110 / 110

页数：1